Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.30)
# 429
Out of 5,182 analysts
120
Total ratings
56.36%
Success rate
14.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Neutral | n/a | $39.48 | - | 9 | Apr 2, 2026 | |
| SLDB Solid Biosciences | Initiates: Buy | $26 | $8.02 | +224.19% | 1 | Mar 20, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $46 → $58 | $26.69 | +117.31% | 4 | Mar 4, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $224 → $284 | $259.00 | +9.65% | 5 | Feb 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $106 → $86 | $54.53 | +57.71% | 5 | Feb 25, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $41 → $45 | $34.76 | +29.46% | 2 | Feb 19, 2026 | |
| PEPG PepGen | Maintains: Buy | $6 → $7 | $1.64 | +326.83% | 3 | Feb 18, 2026 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $20 | $13.50 | +48.15% | 1 | Feb 11, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $64 → $52 | $23.30 | +123.18% | 4 | Jan 5, 2026 | |
| RZLT Rezolute | Maintains: Buy | $15 → $6 | $3.64 | +64.84% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $39 | $26.63 | +46.45% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $19 | $21.18 | -10.29% | 7 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $5.98 | +401.67% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $95 | $15.38 | +517.69% | 7 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $92 | $75.17 | +22.39% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $52.63 | +101.41% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $9.89 | +1.11% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $13.49 | +3.78% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $436.27 | +25.15% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $18.68 | +167.67% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $27.43 | +100.51% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.43 | +424.78% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $11.42 | +48.86% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.46 | +3.73% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $51.22 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.67 | +184.86% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.74 | +488.24% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.72 | +966.18% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $322.11 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $4.49 | +523.61% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.18 | +178.55% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $28.40 | +333.10% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $26.32 | +105.17% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.13 | +5,209.73% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $32.92 | - | 3 | Jun 26, 2017 |
Centessa Pharmaceuticals
Apr 2, 2026
Downgrades: Neutral
Price Target: n/a
Current: $39.48
Upside: -
Solid Biosciences
Mar 20, 2026
Initiates: Buy
Price Target: $26
Current: $8.02
Upside: +224.19%
Maze Therapeutics
Mar 4, 2026
Maintains: Buy
Price Target: $46 → $58
Current: $26.69
Upside: +117.31%
Krystal Biotech
Feb 25, 2026
Maintains: Buy
Price Target: $224 → $284
Current: $259.00
Upside: +9.65%
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Buy
Price Target: $106 → $86
Current: $54.53
Upside: +57.71%
NewAmsterdam Pharma Company
Feb 19, 2026
Maintains: Buy
Price Target: $41 → $45
Current: $34.76
Upside: +29.46%
PepGen
Feb 18, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $1.64
Upside: +326.83%
Entrada Therapeutics
Feb 11, 2026
Initiates: Buy
Price Target: $20
Current: $13.50
Upside: +48.15%
Ultragenyx Pharmaceutical
Jan 5, 2026
Maintains: Buy
Price Target: $64 → $52
Current: $23.30
Upside: +123.18%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $15 → $6
Current: $3.64
Upside: +64.84%
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $26.63
Upside: +46.45%
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $21.18
Upside: -10.29%
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $5.98
Upside: +401.67%
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $15.38
Upside: +517.69%
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $75.17
Upside: +22.39%
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $52.63
Upside: +101.41%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $9.89
Upside: +1.11%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $13.49
Upside: +3.78%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $436.27
Upside: +25.15%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $18.68
Upside: +167.67%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $27.43
Upside: +100.51%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.43
Upside: +424.78%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $11.42
Upside: +48.86%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.46
Upside: +3.73%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $51.22
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $6.67
Upside: +184.86%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.74
Upside: +488.24%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.72
Upside: +966.18%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $322.11
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $4.49
Upside: +523.61%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $7.18
Upside: +178.55%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $28.40
Upside: +333.10%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $26.32
Upside: +105.17%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.13
Upside: +5,209.73%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $32.92
Upside: -